CLIENTRON-CORP.
15.10.2019 15:02:04 CEST | Business Wire | Press release
Clientron Corp., a leading global provider of Thin Client, POS and embedded systems, introduces the brand new all-in-one Thin Client TC238 that features a 23.8” display with fanless and ultra-slim enclosure, and system designed with the concept of Intel® Smart Display Module (Intel® SDM) for optimized display computing. The TC238 AiO thin client runs on client-server architecture and can be implemented with major existing VDI protocols to deliver the best user computing experience for virtual desktop solutions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191015005364/en/
Easy deployment and maintenance to optimize user experience
The TC238 AiO thin client designed with Intel® Smart Display Module (SDM-Large) featuring open pluggable, flexible integration, easy deployment and maintenance design to reduce total cost of ownership.
Energy-efficient and high performance for End user computing
Powered by high performance and power efficient Intel® Braswell x5-E8000 quad core processors, the TC238 AiO thin client supports DDR3L-1600 memory, storage options including mSATA SSD and on-board eMMC storages as manufacturing optional. The I/O connectors include two USB3.2 Gen 1 ports, two USB 2.0 ports, one DisplayPort, one DVI, audio ports as well as networking ability with a M.2 interface for WiFi and Bluetooth functionality.
High-density viewing and space-saving benefits
Featuring ultra-slim enclosure, the TC238 AiO thin client supports 23.8” full HD display and anti-glare panel for comfortable reading. Powered by one wire, it offers streamline and space-saving benefits for operations. In additions, it supports 4K display output to give users a rich, high-density viewing on external monitor.
Enhanced System Security & Virtual Desktop solutions
The TC238 thin client supports Trusted Platform Module (TPM) by manufacturing optional for secure data protection. Moreover, it supports all mainstream virtual desktop protocols including Microsoft RDP/ RemoteFX/WVD, Citrix HDX, and VMware Horizon View to ensure high availability and seamless communication with other applications.
The AiO TC238 thin client features highlight:
- Power-efficient Intel® Braswell x5-E8000 Quad Core Processor with fanless design
- Ultra-slim enclosure with open pluggable Intel® Smart Display Module (SDM-Large)
- Stylish 23.8” Full HD display with LED backlight
- Support up to 4K resolution for external display
- Able to rotate screen to upright position with optional stand
- Adjustable display swivel and tilt angle
- Support two USB 3.2 Gen 1, two USB 2.0, Giga LAN
- Support VESA mount for various mounting solutions
- Support Kensington lock
- Optional Wi-Fi module (M.2 2230 E Key Socket)
- Factory option for eMMC and TPM
The Clientron AiO Thin Client TC238 is available now. For more product details, please contact Clientron sales or visit our website www.clientron.com
About Clientron
Clientron is dedicated to be the professional thin client, POS, Automotive Electronics and embedded computing ODM provider for over 15 years. With providing Design, Manufacturing and Service support abilities for embedded computing, Clientron is your best embedded solution partner to empower more efficiency and safety for your e-World. Visit us at www.clientron.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20191015005364/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom